Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial

Goss, G. D.Cobo, M.Lu, S.Syrigos, K.Lee, K. H.Goker, E.Georgoulias, V.Li, W.Isla, D.Morabito, A.Min, Y. J.Ardizzoni, A.Cseh, A.Bender, S.Felip, E.2019-10-272019-10-2720180923-75341569-8041https://hdl.handle.net/11454/2983743rd ESMO Congress (ESMO) -- OCT 19-23, 2018 -- Munich, GERMANYeninfo:eu-repo/semantics/closedAccessAfatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trialConference Object29WOS:000459277303212Q1